• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Revelation Biosciences Inc.

    11/12/25 4:10:40 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $REVB alert in real time by email
    S-8 1 revb-20251112.htm S-8 S-8

     

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

    REVELATION BIOSCIENCES, INC.

    (Exact name of registrant as specified in its charter)

    Delaware

    84-3898466

    (State or other jurisdiction of
    incorporation or organization)

    (I.R.S. Employer
    Identification No.)

    4660 La Jolla Village Drive, Suite 100

    San Diego, CA 92122

    (Address of principal executive offices, including zip code)

    REVELATION BIOSCIENCES, INC. 2021 EQUITY INCENTIVE PLAN

    (Full title of the plan)

    James Rolke, Chief Executive Officer

    Revelation Biosciences, Inc.

    4660 La Jolla Village Drive, Suite 100

    San Diego, CA 92122

    650-800-3717

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

    Copy to:

     

    Stephen M. Cohen, Esq.
    Lauren W. Taylor, Esq.
    Fox Rothschild LLP

    2001 Market Street, Suite 1700

    Philadelphia, PA 19103

    Telephone: 215-299-2000

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer ☐

    Accelerated filer ☐

    Non-accelerated filer ☒

    Smaller Reporting Company ☒

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     


    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    Item 1. Plan Information

    This Registration Statement is being filed for the purpose of registering 4,647,222 additional shares of common stock, par value $0.001 (“Common Stock”), of Revelation Biosciences, Inc. (the “Registrant”) issuable under the 2021 Equity Incentive Plan (the “Plan”). The Registrant previously filed Registration Statements on Form S-8 covering Common Stock issuable under the Plan (File Nos. 333-265329, 333-273933, and 333-280313) (the “Prior Registration Statements”).

     

    Pursuant to General Instruction E of Form S-8, the contents of the Prior Registration Statements are incorporated by reference in this Registration Statement to the extent not modified or superseded hereby or by any subsequently filed document which is incorporated by reference herein or therein.

    Item 2. Registrant Information and Employee Plan Annual Information

    Upon written or oral request, any of the documents incorporated by reference in Item 3 of Part II of this registration statement (which are incorporated by reference in this Section 10(a) Prospectus) and any other documents required to be delivered to eligible employees, nonemployee directors, and consultants pursuant to Rule 428(b) are available, without charge, by contacting:

    Chester S. Zygmont, III, Chief Financial Officer

    Revelation Biosciences, Inc.

    4660 La Jolla Village Drive, Suite 100

    San Diego, California 92122

    650-800-3717


    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference

    The following documents, as filed with the SEC by Revelation Biosciences, Inc., a Delaware corporation (File No. 001-39603) (the “Company”), pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or the Securities Act are hereby incorporated by reference:

     

    (i)

    Annual Report on Form 10-K for the period ended December 31, 2024, filed with the SEC on March 6, 2025 (the “Registrant Annual Report”);

     

    (ii)

    The Company’s Current Reports on Form 8-K filed on January 7, 2025, January 21, 2025, January 30, 2025, February 11, 2025, February 24, 2025, March 6, 2025, March 17, 2025, May 8, 2025, May 28, 2025, June 4, 2025, June 25, 2025, July 9, 2025, August 8, 2025, September 9, 2025, September 15, 2025, October 15, 2025, October 29, 2025, and November 6, 2025;

     

    (iii)

    Quarterly Reports on Form 10-Q for the period ended March 31, 2025, filed with the SEC on May 8, 2025, the period ended June 30, 2025, filed with the SEC on August 8, 2025, and the period ended September 30, 2025, filed with the SEC on November 6, 2025;

     

    (iv)

    All other reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the Registrant Annual Report; and

     

    (v)

    The description of the Company’s common stock contained in its registration statement on Form S-1 (Registration No. 333-287423) filed with the SEC on May 23, 2025.

     

    All other documents filed by the Company with the SEC pursuant to Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act after the date of this registration statement and before the filing of a post-effective amendment to this registration statement that indicate that all securities offered hereby have been sold, or that deregisters all such securities remaining unsold, will be deemed to be incorporated by reference in this registration statement and to be a part hereof from the date of filing of such documents.

     

    Item 4. Description of Securities

    Not applicable.

    Item 5. Interests of Names Experts and Counsel

    None.


    Item 6. Indemnification of Directors and Officers

    As permitted by Section 102 of the Delaware General Corporation Law, we have adopted provisions in our Third Amended and Restated Certificate of Incorporation, as amended (the “Charter”) and our Second Amended and Restated Bylaws, as amended (the “Bylaws”) that limit or eliminate the personal liability of our directors for a breach of their fiduciary duty of care as a director. The duty of care generally requires that, when acting on behalf of the corporation, directors exercise an informed business judgment based on all material information reasonably available to them. Consequently, a director will not be personally liable to us or our stockholders for monetary damages for breach of fiduciary duty as a director, except for liability for:

     

    ●

    any breach of the director’s duty of loyalty to us or our stockholders;

     

     

    ●

    any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;

     

     

    ●

    any act related to unlawful stock repurchases, redemptions or other distributions or payment of dividends; or

     

     

    ●

    any transaction from which the director derived an improper personal benefit.

     

    These limitations of liability do not affect the availability of equitable remedies such as injunctive relief or rescission. Our Charter also authorizes us to indemnify our officers, directors and other agents to the fullest extent permitted under Delaware law.

     

    As permitted by Section 145 of the Delaware General Corporation Law, our Bylaws provide that:

     

     

    ●

    we may indemnify our directors, officers and employees to the fullest extent permitted by the Delaware General Corporation Law, subject to limited exceptions;

     

     

    ●

    we may advance expenses to our directors, officers and employees in connection with a legal proceeding to the fullest extent permitted by the Delaware General Corporation Law, subject to limited exceptions; and

     

     

    ●

    the rights provided in our amended and restated bylaws are not exclusive.

     

    Our Charter and our Bylaws provide for the indemnification provisions described above and elsewhere herein. We have entered or will enter into, and intend to continue to enter into, separate indemnification agreements with our directors and officers that may be broader than the specific indemnification provisions contained in the Delaware General Corporation Law. These indemnification agreements generally require us, among other things, to indemnify our officers and directors against certain liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct. These indemnification agreements also generally require us to advance any expenses incurred by the directors or officers as a result of any proceeding against them as to which they could be indemnified. These indemnification provisions and the indemnification agreements may be sufficiently broad to permit indemnification of our officers and directors for liabilities, including reimbursement of expenses incurred, arising under the Securities Act of 1933, as amended, or the Securities Act.

    Item 7. Exemption from Registration Claimed

    Not applicable.

     


    Item 8. Exhibits

    Exhibit Number

    Title of Document

    Location

    4.1

    Common Stock Specimen

    Incorporated by reference to the Registration Statement on Form S-1 filed May 23, 2025

    5.1

    Opinion of Fox Rothschild LLP

    This filing

    10.1

    Revelation Biosciences, Inc. 2021 Equity Incentive Plan, as amended

    Incorporated by reference to Appendix A to the definitive proxy statement filed with the SEC on June 6, 2025

    23.1

    Baker Tilly US, LLP

    This filing

    23.2

    Consent of Fox Rothschild LLP

    Included in Exhibit 5.01

    24.1

    Power of Attorney

    See signature page to this filing

    107

    Filing Fee Table

    This filing


    Item 9. Undertakings

    Undertaking Required by Item 512(a) of Regulation S-K: The undersigned registrant hereby undertakes:

     

    (1)

    To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

     

    (i)

    To include any prospectus required by section 10(a)(3) of the Securities Act;

     

    (ii)

    To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

     

    (iii)

    To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.

     

    (2)

    That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3)

    To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    Undertaking Required by Item 512(b) of Regulation S-K: The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to section 15(d) of the Securities Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    Undertaking Required by Item 512(h) of Regulation S-K: Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     


    SIGNATURES

    Pursuant to the requirements of Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in San Diego, California, on the 12th day of November, 2025.

    REVELATION BIOSCIENCES, INC.

    By:

    /s/ James Rolke

    James Rolke

    Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each individual whose signature appears below constitutes and appoints Chester S. Zygmont, III, as his or her true and lawful attorney-in-fact, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto and all documents in connection therewith, with the SEC, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, and hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the date indicated:

    Name and Signature

    Title

    Date

    /s/ James Rolke

    Chief Executive Officer and Director

    November 12, 2025

    James Rolke

    /s/ Chester S. Zygmont, III

    Chief Financial Officer and

    November 12, 2025

    Chester S. Zygmont, III

    Principal Accounting Officer

    /s/ Jennifer Carver

    Director

    November 12, 2025

    Jennifer Carver

    /s/ Jess Roper

    Director

    November 12, 2025

    Jess Roper

    /s/ Lakhmir Chawla

    Director

    November 12, 2025

    Lakhmir Chawla, M.D.

     


    Get the next $REVB alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $REVB

    DatePrice TargetRatingAnalyst
    2/17/2022$12.00Buy
    Roth Capital
    More analyst ratings

    $REVB
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Revelation Biosciences Inc.

    SCHEDULE 13G - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)

    11/14/25 6:15:56 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Revelation Biosciences Inc.

    S-8 - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

    11/12/25 4:10:40 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Revelation Biosciences Inc.

    DEF 14A - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

    11/10/25 2:57:38 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REVB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025

    Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its financial results for the three and six months ended June 30, 2025. Corporate Highlights Completed dosing of patients in PRIME Phase 1b Clinical Study of Gemini in CKD Patients Received gross proceeds of $4 million from public offering in May 2025 "The Revelation team continues to strategically maximize its financial resources to achieve our stated objectives and advance the Gemini program," said James Rolke, Chief Executive Officer of Revelation. "We look forward to announcing data fr

    8/8/25 6:30:00 AM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Revelation Biosciences, Inc. Congratulates Its Former Chairman of the Board, George Tidmarsh, on His Appointment as the Head of the FDA Center for Drug Evaluation and Research

    Revelation Biosciences, Inc. (NASDAQ:REVB) the "Company" or "Revelation") a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, today congratulates its former chairman and shareholder, George Tidmarsh, MD, PhD, who has been selected to head the FDA Center for Drug Evaluation and Research. "George was the chairman of the board of our company, Revelation Biosciences, Inc., as well as one of the founders," said James Rolke, President and CEO, Revelation. "We wish to thank George for his guidance and support during his tenure on the Revelation board as well as for the time we worked together at La Jolla Pharmaceutical Company." Dr. Tidmarsh trained a

    7/24/25 9:00:00 AM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study

    – Sample analysis and data collection ongoing – – Data expected during Q3 2025 – Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, today announced dosing has been completed for the PRIME (PReconditioning IMmunostimulatory Evaluation) Phase 1b clinical study of escalating doses of intravenously administered Gemini in patients with Stage 3 and 4 Chronic Kidney Disease (CKD). As planned, a total of 5 cohorts were enrolled at 3 clinics in the United States. Several study data sets are expected during Q3 2025: these will include safety parameters, changes in hematologic pa

    7/16/25 9:00:00 AM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REVB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Chawla Lakhmir S was granted 15,625 shares, increasing direct ownership by 25,615% to 15,686 units (SEC Form 4)

    4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)

    10/31/25 1:01:10 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Rolke James was granted 390,614 shares, increasing direct ownership by 3,888% to 400,660 units (SEC Form 4)

    4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)

    10/31/25 12:58:15 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Carver Jennifer was granted 15,625 shares, increasing direct ownership by 24,802% to 15,688 units (SEC Form 4)

    4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)

    10/31/25 12:56:12 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REVB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on Revelation Biosciences with a new price target

    Roth Capital initiated coverage of Revelation Biosciences with a rating of Buy and set a new price target of $12.00

    2/17/22 8:17:25 AM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REVB
    Leadership Updates

    Live Leadership Updates

    View All

    Revelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of Directors

    Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced the retirement of George F. Tidmarsh, MD, PhD from the Company's Board of Directors. "The team at Revelation wholeheartedly thanks Dr. Tidmarsh for his guidance and support over the past 5 years," said James Rolke, Chief Executive Officer of Revelation. "While he will be missed, we wish him the best of luck in his newest endeavor." "The Revelation team is dedicated to developing innovative therapies to improve the clinical outcomes for patients in need," said Dr. Tidmarsh. "I thank them for their passio

    5/23/25 4:05:00 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025

    – A vote for Proposal 2 saves the Company over $200,000 per year – Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, wants to remind all shareholders to vote their proxies for the January 17, 2025 special meeting of stockholders. In particular, a vote for Proposal 2, the redomicile of the Company from Delaware to Nevada will save the Company at least $200,000.00 per year in franchise tax fees. All proposals in the proxy are important and the Board of Directors has suggested a vote for all proposals. Please vote by calling Advantage Pr

    1/13/25 6:00:00 AM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Revelation Biosciences Inc. Announces Appointment of Lakhmir Chawla, M.D. to Board of Directors

    Revelation Biosciences Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today announced the appointment of Lakhmir Chawla M.D. to the Company's Board of Directors (Board). "We are excited to welcome Dr. Chawla as an independent director to our Board," said James Rolke, Chief Executive Officer of Revelation. "Dr. Chawla brings decades of expertise and leadership in key areas such as nephrology, critical care medicine, drug development and strategic implementation. I am confident that he will provide valuable perspectives as we continue to execute our str

    10/2/23 9:00:00 AM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REVB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Revelation Biosciences Inc. (Amendment)

    SC 13G/A - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)

    2/13/24 8:12:05 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Revelation Biosciences Inc.

    SC 13G - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)

    1/3/24 8:36:37 AM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Revelation Biosciences Inc.

    SC 13G - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)

    2/21/23 4:49:56 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REVB
    Financials

    Live finance-specific insights

    View All

    Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025

    Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its three months ended March 31, 2025 financial results. Corporate Highlights Announced a new indication for Gemini in severe burn patients Released data showing Gemini priming attenuated inflammation in peripheral blood mononuclear cells Completed dosing of first patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients "While we continue to expand the pipeline here at Revelation, we are excited to continue our collaboration with Vanderbilt and Dr. Bohannon in the area of severe bu

    5/8/25 4:15:00 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024

    Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its three and twelve months ended December 31, 2024 financial results. Corporate Highlights Announced dosing of first patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients Announced start of its PRIME Phase 1b Clinical Study of Gemini in CKD Patients Announced FDA Acceptance of Gemini IND Received net proceeds of $3.7 million from the exercise of warrants in December 2024 "We made significant progress at the end of last year and hope to continue that pace in 2025," said James

    3/6/25 4:15:00 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024

    Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, today reported its three and nine months ended September 30, 2024 financial results. Corporate Highlights Completed GMP manufacture of Gemini clinical drug supply Received net proceeds of $3.8 million from the exercise of warrants in August 2024 Announced Gemini induces dose dependent significant increases in IL-10 in healthy volunteers "The Revelation team continues to make significan

    11/8/24 4:15:00 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care